



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 51793

Title: Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study

Reviewer’s code: 03477219

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor

Reviewer’s country: Italy

Author’s country: China

Reviewer chosen by: Artificial Intelligence Technique

Reviewer accepted review: 2019-10-18 14:42

Reviewer performed review: 2019-10-19 10:36

Review time: 19 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Authors aimed to evaluate effects and mechanism of rifaximin in the treatment of refractory ascites by studying 75 cirrhotic patients (50 treated and 25 as controls). Authors conclude that rifaximin has an effect in improving ascites treatment as well as in survival, maybe due to its capacity in modulation of microbiota. The papers is interesting and provide important addressees for the management of cirrhotic patients. This is a study on clinical practice, and this mitigates the major limit of this study: the lack of a sample size calculation and of randomization of patients between treatment arms. Please clarify how was refractory ascites diagnosed and the choiche of that conventional therapy (oral diuretic: furosemide 80 mg/d + spironolactone 160 mg/d). Authors include in the study ascitic patients both with SBP and not. Please discuss the reason. Please analyze patients survival using competing risk analysis.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 51793

Title: Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study

Reviewer's code: 00188507

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor, Lecturer

Reviewer's country: Japan

Author's country: China

Reviewer chosen by: Artificial Intelligence Technique

Reviewer accepted review: 2019-10-18 15:55

Reviewer performed review: 2019-10-21 22:54

Review time: 3 Days and 6 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

The authors conducted the observational study to clarify the effect of rifaximin on the cases of liver cirrhosis complicated with the refractory anemia. The results of clinical outcomes and the structure and function of intestinal bacteria are well understandable and as an observational study, they have provided the necessary information regarding the prognosis. Therefore, this manuscript can be published in the journal as an observational study.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No